Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

BACKGROUND: Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammel, P, Kindler, H L, Reni, M, Van Cutsem, E, Macarulla, T, Hall, M J, Park, J O, Hochhauser, D, Arnold, D, Oh, D -Y, Reinacher-Schick, A, Tortora, G, Algül, H, O’Reilly, E M, McGuinness, D, Cui, K Y, Joo, S, Yoo, H K, Patel, N, Golan, T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938600/
https://www.ncbi.nlm.nih.gov/pubmed/31562758
http://dx.doi.org/10.1093/annonc/mdz406

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938600/
https://www.ncbi.nlm.nih.gov/pubmed/31562758
http://dx.doi.org/10.1093/annonc/mdz406

Ejemplares similares